GLP-1 Drug Impact Reaches ANZ; New Zealand Diversifies F&B Exports
GLP-1 drug awareness in ANZ hits 78%, reshaping consumer food purchasing. Simultaneously, New Zealand aims to broaden its F&B export portfolio beyond dairy, focusing on high-value, evidence-based nutrition products.
Emerging data from Australia and New Zealand (ANZ) highlights the escalating impact of GLP-1 weight-loss medications on consumer behaviour, mirroring trends previously observed in North America and Europe. NIQ Homescan data indicates 78% awareness of GLP-1 drugs across ANZ, a significant 5-percentage-point increase within one quarter. Furthermore, 55% of consumers in the region expressed willingness to consider using these medications. This rapid uptake suggests a substantial, impending shift in purchasing habits, particularly towards products supporting weight management and satiety, and a potential reduction in demand for high-calorie, indulgence-focused items. Supplement brands must anticipate changes in ingredient preferences and product positioning to align with evolving consumer needs.
Concurrently, New Zealand is strategically expanding its global food and beverage (F&B) export profile beyond its well-established dairy sector. Historically, over 90% of New Zealand's dairy production is exported, renowned for its grass-fed systems and stringent quality standards. However, New Zealand Trade and Enterprise Head of Business Development, Erika Sirimanne, stated the nation intends to pivot from a product-focused mindset to one emphasising evidence-based nutrition. This initiative seeks to elevate other high-potential food and nutrition categories, aiming for the same international recognition dairy currently enjoys. This shift signals increased availability of diverse, quality ingredients and finished products from New Zealand, driven by a national strategy to diversify export revenue streams.
The global coffee market also faces unprecedented volatility, with prices spiking to 50-year highs in early 2025 and mid-2026. Arabica coffee prices reached US$4.40 per pound in February 2025, driven by climate-induced yield reductions in Brazil, which accounts for 35% of global coffee supply. This volatility impacts input costs for supplement manufacturers utilising coffee-derived ingredients, such as caffeine or green coffee extract, and underscores the need for robust supply chain diversification and risk mitigation strategies.
What this means for Australia and New Zealand
Brand owners in ANZ must immediately assess product portfolios for alignment with GLP-1-driven dietary shifts, prioritising nutrient density, satiety, and targeted weight management solutions. Reformulation windows for existing lines will be tight, requiring rapid R&D and manufacturing adjustments to meet emerging demand for low-calorie, high-protein, or fibre-rich supplements. Procurement teams should explore New Zealand's expanding 'evidence-based nutrition' export offerings, which could provide novel, high-quality ingredients with verifiable claims. Contract manufacturers should prepare for increased demand for tailored, functional formulations, potentially requiring new accreditations or processing capabilities to leverage the national export diversification strategy. Competitive advantage will accrue to those who quickly adapt to the 55% of consumers considering GLP-1 usage.
Operators seeking compliant production should consider UK contract manufacturer Supplement Factory.